Peter H. Wiernik
About
In The Last Decade
Peter H. Wiernik
503 papers receiving 18.4k citations
Hit Papers
Peers
Comparison fields: 5 of 160
- Oncology 7.1k
- Hematology 6.4k
- Molecular Biology 5.2k
- Public Health, Environmental and Occupational Health 3.4k
- Pathology and Forensic Medicine 3.2k
Countries citing papers authored by Peter H. Wiernik
This map shows the geographic impact of Peter H. Wiernik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter H. Wiernik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter H. Wiernik more than expected).
Fields of papers citing papers by Peter H. Wiernik
This network shows the impact of papers produced by Peter H. Wiernik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter H. Wiernik. The network helps show where Peter H. Wiernik may publish in the future.
Co-authorship network of co-authors of Peter H. Wiernik
This figure shows the co-authorship network connecting the top 25 collaborators of Peter H. Wiernik. A scholar is included among the top collaborators of Peter H. Wiernik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter H. Wiernik. Peter H. Wiernik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 6 | |
| 4 | 15 | |
| 5 | Renal cell carcinoma in patients with a personal or family history of hematologic malignancies. | 5 |
| 6 | 86 | |
| 7 | 300 | |
| 8 | In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) breakdown → | 537 |
| 9 | 104 | |
| 10 | 7 | |
| 11 | 51 | |
| 12 | 3 | |
| 13 | 19 | |
| 14 | 19 | |
| 15 | The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. | 103 |
| 16 | 12 | |
| 17 | Variable reactivity of monoclonal antibodies (MAB) against the X-hapten indicates structural differences in the X-determinant expressed on Hodgkin's (HD) and other cell lines: Effect of neuraminidase treatment (NT) | 1 |
| 18 | 4 | |
| 19 | Meningeal carcinomatosis from small cell carcinoma of the lung. Consequence of improved survival. | 15 |
| 20 | Phase II study of dianhydrogalactitol in malignant glioma. | 10 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.